Health Condition 1: N186- End stage renal disease
Conditions
Interventions
Intervention1: L-Arginine: Oral L-Arginine, 9 grams per session, 3 times per week for 4 weeks, dissolved in water
Control Intervention1: Placebo (cellulose powder): Placebo (cellulose powder) in ident
Sponsors
Dr Omkar Sonavane
Eligibility
Inclusion criteria
Inclusion criteria: 1. ESRD (CKD Stage 5) on maintenance hemodialysis more than or equal to 3 months. 2.IDHtn (SBP rise more than or equal to 10 mmHg from pre- to post-dialysis in more than 30 percent of sessions over 4 weeks). 3. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Intradialytic hypotension. 2. Known allergy to L-Arginine. 3. Participation in another interventional trial within 30 days. Before and during the course of study 4. Active infection, severe hepatic impairment, sepsis, or systemic inflammation. 5. Ischemic heart disease, heart failure, or use of nitrates or PDE-5 inhibitors. 6. Hyperkalemia (potassium more than 5.5 mEq per Litre).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants with IDHtn (SBP rise morethan or equal to 10 mmHg from pre- to post-dialysis in morethan or equalto 30 percentage of sessions)Timepoint: 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| SBP or MAP variability (mean SD), adverse events (graded by CTCAE v5.0), frequency and severityTimepoint: 4 weeks | — |
Countries
India
Contacts
Public ContactDr Omkar Sonavane
Gadag Institute of Medical Sciences, Gadag
Outcome results
None listed